Nuvo Pharmaceuticals (MRVFF) Stock Price, News & Analysis

Company Overview

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $0.98 to $0.98
• 50-Day Range: $0.98 to $0.98
• 52-Week Range: $0.42 to $1.25
• Volume: N/A
• Average Volume: 11,250 shs
• Market Capitalization: $11.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MRVFF Stock Analysis - Frequently Asked Questions

How have MRVFF shares performed this year?

Nuvo Pharmaceuticals' stock was trading at $0.9795 at the beginning of the year. Since then, MRVFF shares have increased by 0.0% and is now trading at $0.9795.

How do I buy shares of Nuvo Pharmaceuticals?

Shares of MRVFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MRVFF
• CIK: N/A
• Web: www.nuvopharmaceuticals.com
• Phone: (905) 673-6980
• Fax: 905-673-1842
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.70 million
• Net Margins: 20.88%
• Pretax Margin: 25.58%
• Return on Equity: -1,996.22%
• Return on Assets: 14.25%

Debt

• Debt-to-Equity Ratio: 9.97
• Current Ratio: 2.11
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $54.98 million
• Price / Sales: 0.20
• Cash Flow: $0.09 per share
• Price / Cash Flow: 11.09
• Book Value: ($0.80) per share
• Price / Book: -1.22

Miscellaneous

• Outstanding Shares: 11,400,000
• Free Float: 10,602,000
• Market Cap: $11.17 million
• Optionable: Not Optionable
• Beta: 0.98